Title : Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

Pub. Date : 2018 Apr

PMID : 29368537






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We previously demonstrated superior efficacy and safety advantages in HIV-infected, virologically suppressed adults switched to a regimen containing tenofovir alafenamide (TAF) as compared with those remaining on a tenofovir disoproxil fumarate (TDF) regimen through week 48. Tenofovir TATA-box binding protein associated factor 8 Homo sapiens